Vanda Pharmaceuticals Stock News

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q4 2021 Results - Earnings Call Transcript

Vanda Pharmaceuticals GAAP EPS of $0.12, revenue of $68.01M

WASHINGTON, Feb. 23, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021. "We are proud of the progress we have made this past year with our existing products…

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is $0.09

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET on…

WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23,

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) price on Friday, February 11, rose 1.73% above its previous days close as an upside momentum from buyers pushed the stocks value to $13.52. A look at the stocks price movement, the close in the last trading session was $13.29, moving within a range at $13.24 and $13.85. The beta value Vanda Pharmaceuticals Inc. (VNDA) Is A Possible Investment At Current Levels Read More »

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.  Gastroparesis is a condition t

Vanda Pharmaceuticals Inc (NASDAQ: VNDA ) shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis. Gastroparesis is a condition that reduces the ability of the stomach to empty its contents. It does not involve a blockage (obstruction). The study did not meet its prespecified primary endpoint , the difference between drug and placebo on the severity of nausea from baseline at Full story available on Benzinga.com

Vanda Pharmaceuticals'' (VNDA) medicine tradipitant failed to beat placebo in a phase 3 trial to treat symptoms of gastroparesis.The study, dubbed VP-VLY-686-3303, did not meet its main

Vanda Pharmaceuticals Inc  VNDA shares are plunging after the company announced Phase 3 trial data of tradipitant in treating the symptoms of gastroparesis.  Get the Inside Access Traders Are Using

Vanda Pharmaceuticals (VNDA) has entered into a License Agreement with MSN Pharmaceuticals, MSN Laboratories, and Impax Laboratories in a bid to resolve its patent litigation against

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating sentiment. The week's news w

WINTON GROUP Ltd reduced its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 70,292 shares of the biopharmaceutical companys stock after selling 11,286 shares during the quarter. WINTON GROUP Ltd []

Related Stocks: VNDA ,